Basal cell nevus syndrome l.jpg
This presentation is the property of its rightful owner.
Sponsored Links
1 / 43

Basal Cell Nevus Syndrome PowerPoint PPT Presentation


  • 73 Views
  • Uploaded on
  • Presentation posted in: General

Basal Cell Nevus Syndrome. Daniel Berg M.D., FRCPC Director, Dermatologic Surgery University of Washington. Thank Goodness….. Shade at Last!. Basal Cell Nevus Syndrome. Autosomal Dominant 50% risk of passing on In the skin: Numerous Basal Cell Carcinomas Beginning at young age

Download Presentation

Basal Cell Nevus Syndrome

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Basal cell nevus syndrome l.jpg

Basal Cell Nevus Syndrome

Daniel Berg M.D., FRCPC

Director, Dermatologic Surgery

University of Washington


Slide2 l.jpg

Thank Goodness….. Shade at Last!


Basal cell nevus syndrome3 l.jpg

Basal Cell Nevus Syndrome

  • Autosomal Dominant

    • 50% risk of passing on

  • In the skin:

    • Numerous Basal Cell Carcinomas

      • Beginning at young age

      • Sensitivity to Radiation Treatment

    • Palmar Pits


Basal cell carcinoma bcc l.jpg

BASAL CELL CARCINOMA (BCC)

  • Commonest Cancer U.S.800,000/yr

    • 99% in Caucasians

    • 95% between age 40-79

    • 85% on Head & Neck

    • Risk of Metastasis: Very Very Low

    • Main potential problem: Local Invasion


Epidemiology l.jpg

EPIDEMIOLOGY

LIFETIME RISK OF BCC AND SCC

MEN:18.6%

WOMEN:18%

(based on B.C. data - lifespan 75 yrs.)


Bcns time of onset bcc l.jpg

BCNS Time of Onset BCC

  • Before puberty:15%

  • By age 22:50%

  • By age 35:90%

  • None over age 30: 10%


Remember this l.jpg

Remember this?

  • DNA molecules make up genes

  • Genes are blueprints for Proteins

  • Proteins are the building blocks of body functions

  • Some proteins control cell growth

P

M

D

  • Everyone has two copies of each gene

  • One each from Mum and Dad


Slide8 l.jpg

Tumor Suppressors

Proteins that normally act as brake on cell growth.

P

Patched

Smo

Inhibits

Downstream

Target Genes

Growth

Induces


Patched l.jpg

Patched

P

P

Normal

Cell

Cell at Risk

BCC Cell


Slide10 l.jpg

UVB

Ultraviolet Light


Slide11 l.jpg

Spring Break - circa 1900


Basal cell carcinoma l.jpg

BASAL CELL CARCINOMA

  • CLINICAL PRESENTATION

  • Nodular

  • Superficial

  • Morpheaform

  • Pigmented


Slide14 l.jpg

Nodular


Slide15 l.jpg

Superficial


Slide16 l.jpg

Pigmented


Slide17 l.jpg

Morpheaform


Slide18 l.jpg

Infiltrative


Nonmelanoma skin cancer l.jpg

NonMelanoma Skin Cancer

Choice of Treatment

Balance:

CURE RATE

FUNCTIONAL RESULT

COSMETIC RESULT


Choice of treatment l.jpg

Choice of Treatment

  • Special Features in BCNS Patients:

    • Numerous BCCs expected

      • Save more complicated surgery

      • Early detection more important

    • Size

    • Consequences if recurrence

    • Pathology

    • Patient Concerns


Treatments l.jpg

Treatments

  • Topical

    • 5FU (Effudex)

      • Superficial only

    • Imiquimod (Aldara)

      • Just approved by FDA 2004

  • Surgery

    • ED&C (scrape and burn)

    • Excision

      • Mohs

      • Regular


Treatments22 l.jpg

Treatments

  • Radiation

    • Not in BCNS

  • Other

    • PDT


Ed c scrape burn l.jpg

ED & C (“scrape & burn”)

CURE FOR SMALL PRIMARIES >90%

  • ADVANTAGES

    • Inexpensive

    • Outpatient Office Procedure

    • Quick

  • DISADVANTAGES

    • High Recurrence Rate for Difficult Tumors

      • Location, recurrent, deep


Slide24 l.jpg

ED&C

Initial Lesion (BCC)

Curettage (after biopsy)


Slide25 l.jpg

ED&C

Desiccation

Repeat X 3


Slide26 l.jpg

Final Defect

ED&C

Typical Scar


Surgical excision l.jpg

SURGICAL EXCISION

CURE FOR PRIMARY TUMORS > 90%

  • ADVANTAGES

    • Inexpensive

    • Often office or outpatient procedure

  • DISADVANTAGES

    • More difficult with recurrent, indistinct tumors

    • Margin control difficult in some locations


Slide28 l.jpg

PDT

  • Not approved for BCC in USA

  • Combination of Drug + LightEffect

    • Drug can be given as cream, by mouth or iv.

    • Currently two topicals approved in USA (AK)

      • Levulan Kerastick

      • Metvix

    • Some studies in BCC exist

      • Metvix - 70% Cure at 2 years (Arch Derm 2004)


Slide29 l.jpg

PDT

PDT Pathway

PDT Selectivity


Topical imiquimod aldara l.jpg

Topical Imiquimod (Aldara)

  • Approved FDA 2004 for Superficial BCC

    • 5 nights per week

    • Total 6 week course

    • Cure 70-85%

    • Not tested in lesions <1cm from eyes, nose, mouth, ears

    • Largest diameter 2cm

  • Side Effects

    • Significant irritation at site common


Topical imiquimod l.jpg

Topical Imiquimod

  • Possible role in nodular BCC

    • Cure Rates 12 weeks:

      • Once daily 5nights per week: 70%

      • Twice daily 7 nights per week: 76%

      • Once daily 3 nights/ week: 60%

    • Cure Rates 6 weeks

      • Similar


Mohs micrographic surgery l.jpg

MOHS MICROGRAPHIC SURGERY

  • Definition:

    • The multistage excision of (non-melanoma skin) cancer using meticulous histologic examination of horizontal sections of removed tissue to guide the excision.

    • Allows maximal preservation of normal tissue with the highest published cure rates for selected tumors.


Mohs micrographic surgery33 l.jpg

MOHS MICROGRAPHIC SURGERY

  • Useful for difficult tumors with lower cure rates with standard methods:

    • Recurrent

    • Large

    • Difficult Anatomic Locations on Face

    • Clinically indistinct (ie margins difficult to ascertain)

    • Aggressive Pathology (Sclerosing)


Slide34 l.jpg

WHERE TO

CUT?

3 - 4mm margin


Slide35 l.jpg

2. Excise Stage 1

1. “Debulk”

Mohs Micrographic Surgery

2. Excise Stage 1

Initial Defect


Slide36 l.jpg

3. Prepare Tissue

1. “Debulk”

Initial Defect


Slide37 l.jpg

Prepare Tissue

(Patient Waits)


Slide38 l.jpg

Taking residual Tumor - Stage II

Map Stage 1

Positive


Slide39 l.jpg

Repairing Defect

Clear Margins


Slide40 l.jpg

  • Hierarchy of Options

  • 2nd Intention

  • Primary Closure

  • Skin Graft

  • -FTSG

  • -STSG

  • Local Flap

  • -Advancement

  • -Rotation

  • -Transposition

  • -Pedicle

  • 2-Stage Local Flap

  • Combination Repair

  • Other

  • -Free Flap

  • -Tissue Expansion


Slide43 l.jpg

The End


  • Login